An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse

Trial Profile

An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2016

At a glance

  • Drugs Iodine I 131 derlotuximab biotin (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Feb 2010 Long-term follow-up data reported in Current Cancer Therapy Reviews, as reported by Peregrine Pharmaceuticals.
    • 19 Oct 2007 Status changed from in progress to completed.
    • 13 Jun 2007 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top